Results grounded in experimental data—not abstracts.
Press Enter ↵ to solve
Fuel Your Discoveries
"The most beautiful experience we can have is the mysterious."
- Albert Einstein
Quick Explanation
Copied
Battle-tested verdict on: “Somatic noncoding mutation: de novo SE → oncogene dependency”
Your proposed causal chain is plausible, but the provided evidence set supports partial links (noncoding→regulatory gain and regulatory→oncogene-like output) more strongly than it supports the full enhancer causality → oncogene dependency endpoint in a single, end-to-end demonstration.
Strongest supported steps in the provided papers:
Somatic noncoding mutations can create/reshape regulatory control (e.g., de novo enhancer mutations bound by TARZN complex to regulate TAL1 in T-ALL)
Noncoding driver regulatory elements exist and can be functionally validated at least for specific loci (e.g., TOP2B-bound FMREs; RMRP validated as a cancer driver via in vivo/in vitro editing)
Large-scale screens provide functional support that rare noncoding variants can regulate cancer-driver gene expression (e.g., MapUTR 3′UTR variant activity; includes miRNA/RBP mechanisms; some variants affect proliferation in edited cells)
Distribution-based signals support positive selection in some noncoding regulatory regions, including promoter-level signals in melanoma/pan-cancer datasets
What is missing / weaker in this evidence bundle: a direct demonstration that editing a specific de novo super-enhancer (SE) causally creates oncogene dependency (e.g., enhancer perturbation → loss of essentiality/sensitivity for the relevant oncogene) in the same tumor context and with dependency-style readouts.
Long Explanation
Evidence-battleboard: “Somatic noncoding mutation : de novo SE → oncogene dependency”
You supplied a set of papers that collectively touch (i) noncoding regulatory mutation binding/function, (ii) noncoding driver regulatory element validation, and (iii) cancer-driver expression/proliferation effects of noncoding variants. However, the full causal chain “de novo SE → oncogene dependency” is not consistently demonstrated end-to-end in the provided bundle.
1) What we can claim with higher confidence (supported links)
Noncoding mutation can be bound and activate oncogenic gene expression.
TARZN complex binding to de novo enhancer mutations promotes oncogenic TAL1 expression in T-ALL models, supported by biochemical binding and expression-regulation perturbations.
Noncoding regulatory elements can be cancer drivers and be functionally validated.
TOP2B-bound frequently mutated regulatory elements (FMREs) are enriched for mutational/SV hotspots and cancer-gene associations; importantly, one promoter-region FMRE (RMRP) is validated as a cancer driver via in vivo and in vitro editing.
Many rare/somatic noncoding variants have measurable regulatory effects on cancer-relevant transcripts; some alter proliferation.
MapUTR screens 3′UTR variants regulating mRNA abundance of cancer-driver genes; selected genome-edited alleles change mRNA stability/expression and can shift proliferation phenotypes in the tested cell systems.
Noncoding regions can show positive-selection-like mutation distribution patterns beyond coding.
SEISMIC detects driver-like signals using mutation distribution skew across tumor cohorts (orthogonal to simple recurrence). It reports significant promoter-region signals (e.g., TERT promoter in melanoma/promoter analyses) while emphasizing confounding risks and modeling dependence.
2) Where the evidence chain is weak or incomplete (key missing causal steps)
Causal gap analysis
“de novo SE” specificity: Only one of your provided papers explicitly frames de novo enhancer mutations (TARZN/TAL1 in T-ALL). The TOP2B paper discusses FMREs/promoters and mutational processes; it is not framed as “de novo super-enhancer” creation in the same sense.
Oncogene dependency endpoint: The provided bundle contains evidence for regulatory control and expression/proliferation effects, but it does not consistently provide the hallmark “oncogene dependency” readout (e.g., tumor-essentiality or dependency scores) specifically tied to editing a single de novo SE element. TARZN supports expression regulation of TAL1; TOP2B supports driver function at RMRP; MapUTR shows allele-specific expression/proliferation effects in engineered clones—but neither package, as provided, closes the full dependency loop in the exact “de novo SE → oncogene dependency” form.
Attribution vs correlation (especially for many candidate noncoding drivers): TOP2B’s FMRE-to-driver landscape contains extensive correlational evidence, and SEISMIC relies on mutation probability modeling (with explicit sensitivity to hotspots and modeling choices). That means the chain “mutation created enhancer function that caused oncogene dependency” remains partly inferential unless each step is experimentally closed.
3) Visual evidence synthesis (from the numbers present in your provided data)
3.1 SEISMIC: scale of detected driver-like signals
Numbers are taken from the provided SEISMIC excerpt: .
Scale values come from the provided MapUTR excerpt. .
3.3 Concept graph: mapping evidence to the chain
The diagram is not a score; it visualizes which parts of the chain the provided papers directly address. The missing/weak link is the explicit oncogene dependency endpoint in response to editing a specific de novo SE element.
4) How to improve/upgrade this evidence claim (what would “strong” look like)
Minimum experimental closure needed to truly support “de novo SE → oncogene dependency”
Demonstrate that the specific somatic noncoding mutation is present and maps to a super-enhancer-like regulatory state in the relevant tumor context (chromatin/SE annotations).
Causally perturb only the mutation-containing SE using targeted editing or SE-specific repression (not just a transcription factor knockdown) and measure loss of oncogene expression (TAL1/oncogene output).
Measure dependency using orthogonal essentiality-style readouts (e.g., dependency scoring, viability effects tied to oncogene). The provided papers show expression regulation and some proliferation effects, but the excerpt bundle does not explicitly close this endpoint for a de novo SE.
Rescue/recapitulation: reintroduce the allele or restore enhancer activity and show dependency returns, ruling out off-target editing and background mutational effects.
5) Skeptical conclusion (with confidence level)
Best-evidence status from your supplied papers:Moderate support for noncoding→oncogenic regulatory output; weaker/partial support for the full “de novo SE → oncogene dependency” endpoint as explicitly stated.
Confidence: ~6/10 for “noncoding regulatory mutations can drive oncogene expression/pro-survival programs,” but ~3–4/10 for “SE-level de novo mutation creation directly causes oncogene dependency” in the strict sense, given the bundle’s missing explicit dependency end-to-end readout.
Analyzes the provided SEISMIC and MapUTR summary counts to generate comparative plots and a chain-coverage table that highlights which causal steps are supported vs missing.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A “noncoding mutations → oncogene dependency” model that ignores enhancer context (SE state, 3D contacts, and dependency readouts) will fail because multiple noncoding drivers can modulate expression without becoming essential in every genetic background—expression ≠ essentiality.
Treating mutation-selection signals (e.g., SEISMIC promoter skew) as equivalent to direct SE causal dependency will overclaim; distribution models can be confounded by hotspot processes and mutation probability modeling choices.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
